401 Episodes

  1. Episode 323 ASCO24: TDXD in Bladder Cancer

    Published: 6/2/2024
  2. Episode 322 ASCO24: The role of ctDNA in the TheraP trial (LuPSMA vs cabazitaxel in CRPC)

    Published: 6/2/2024
  3. Episode 321 ASCO24: CHAARTED-2 in prostate cancer - is the sequel as good as the original?

    Published: 6/1/2024
  4. Episode 320: Team Canada's entry for the Uromigos Cup

    Published: 5/25/2024
  5. Episode 319: ASCO 2024: A Preview of GU Data

    Published: 5/19/2024
  6. Episode 318: The Lancet Commission on prostate cancer: planning for a surge in cases

    Published: 5/13/2024
  7. Episode 317: AUA 2024 Preview with the AUA Secretary

    Published: 5/1/2024
  8. Episode 316: APCCC 2024 Summary with Silke Gillessen

    Published: 4/28/2024
  9. Episode 315: APCCC 2024 Quickfire - Bone health, hot flashes and gynecomastia in prostate cancer

    Published: 4/27/2024
  10. Episode 314: APCCC 2024 Cardiovascular risks with hormone therapy in prostate cancer

    Published: 4/27/2024
  11. Episode 313: APCCC 2024 Debate - Radiation therapy in advanced disease

    Published: 4/26/2024
  12. Episode 312: APCCC 2024 Radiation therapy after surgery for prostate cancer

    Published: 4/26/2024
  13. Episode 311: The Uromigos Paper of the Month - The POUT Trial

    Published: 4/23/2024
  14. Episode 310: Dosing and duration of drugs from a cost perspective

    Published: 4/17/2024
  15. Episode 309: EAU24 Checkmate 274 - OS for adjuvant nivolumab in bladder cancer

    Published: 4/7/2024
  16. Episode 308: EAU24 IMVIGOR 011 - Outcome of ctDNA negative patients post-cystectomy

    Published: 4/7/2024
  17. Episode 307: Bladder-Sparing Approaches Part 2

    Published: 4/2/2024
  18. Episode 306: The Uromigos Paper of the Month - Chemo/Nivo as a bladder sparing approach in UC

    Published: 3/28/2024
  19. Episode 305: FDA and Oncology Clinical Trials

    Published: 3/19/2024
  20. Episode 304: A PSMA CD3 Bispecific T-cell Engager in CRPC

    Published: 3/11/2024

5 / 21

Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is a Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London